Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats

Am J Nephrol. 2008;28(1):25-33. doi: 10.1159/000108758. Epub 2007 Sep 20.

Abstract

Background/aim: We examined the influence of chronic treatment with angiotensin-(1-7) [Ang-(1-7)] on renox (renal NADPH oxidase, NOX-4) and the development of renal dysfunction in streptozotocin-treated spontaneously hypertensive rats (diabetic SHR).

Methods: Mean arterial pressure, urinary protein and vascular responsiveness of the isolated renal artery to vasoactive agonists were studied in vehicle- or Ang-(1-7)-treated SHR and diabetic SHR.

Results: Ang-(1-7) decreased the elevated levels of renal NADPH oxidase (NOX) activity and attenuated the activation of NOX-4 gene expression in the diabetic SHR kidney. Ang-(1-7) treatment increased sodium excretion but did not affect mean arterial pressure in diabetic SHR. There was a significant increase in urinary protein (266 +/- 22 mg/24 h) in the diabetic compared to control SHR (112 +/- 13 mg/24 h) and treatment of diabetic SHR with Ang-(1-7) reduced the degree of proteinuria (185 +/- 23 mg/24 h, p < 0.05). Ang-(1-7) treatment also attenuated the diabetes-induced increase in renal vascular responsiveness to endothelin-1, norepinephrine, and angiotensin II in SHR, but significantly increased the vasodilation of the renal artery of SHR and diabetic SHR to the vasodilator agonists.

Conclusion: These results suggest that treatment with Ang-(1-7) constitutes a potential therapeutic strategy to alleviate NOX-mediated oxidative stress and to reduce renal dysfunction in diabetic hypertensive rats.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin I / pharmacology*
  • Animals
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects
  • Body Weight
  • Diabetes Mellitus, Experimental / complications
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / physiopathology
  • Enzyme Activation / drug effects
  • Gene Expression Regulation, Enzymologic / drug effects
  • Hyperglycemia / complications
  • Hypertension, Renal / drug therapy*
  • Hypertension, Renal / etiology
  • Hypertension, Renal / physiopathology
  • Male
  • NADPH Oxidase 4
  • NADPH Oxidases / genetics
  • NADPH Oxidases / metabolism*
  • Peptide Fragments / pharmacology*
  • Proteinuria / complications
  • Proteinuria / drug therapy
  • Proteinuria / physiopathology
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Renal Circulation / drug effects
  • Vasoconstriction / drug effects
  • Vasodilation / drug effects

Substances

  • Antihypertensive Agents
  • Peptide Fragments
  • Angiotensin I
  • NADPH Oxidase 4
  • NADPH Oxidases
  • Nox4 protein, rat
  • angiotensin I (1-7)